Early clinical trial results, presented at addiction medicine conferences in 2024 and 2025, have reported that participants on semaglutide experienced fewer heavy drinking days, lower craving scores on validated assessment tools, and in some cohorts spontaneous reductions in other substance use that wasnt being directly targeted
Retrieved from Heslin, A
bu da kan ekeri seviyelerinin uzun sreli inslin tedavisine gerek kalmadan stabilize olmas anlamna gelir
Proc Nat Acad Sci
It's very exciting to have, especially since it's more of a noninvasive strategy compared to bariatric surgery, and a lot more patients will be open to it.
M., Jr, Wang, Q., Wolski, K., Davey, D., Kalahasti, V., Khan, N., Miller, M